POFUT1 as a Promising Novel Biomarker of Colorectal Cancer

Chabanais, Julien; Labrousse, François; Chaunavel, Alain; Germot, Agnès; Maftah, Abderrahman

doi:10.3390/cancers10110411

Cited by 33 publications

(36 citation statements)

References 65 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Serum-based biomarkers are of considerable importance in the early diagnosis of various diseases including cancers (27,28). In recent years, the public availability of cancer gene expression data, such as Oncomine databases and TCGA databases, has provided a unique opportunity to explore initial hypotheses and concepts that can subsequently be validated by additional experiments (29)(30)(31). There was much higher APOC1 expression in serum of GC than that in adjacent tissues of GC and normal control.…”

Section: Discussionmentioning

confidence: 99%

Apolipoprotein C1 (APOC1) as a novel diagnostic and prognostic biomarker for gastric cancer

Ren

et al. 2019

Ann. Transl. Med.

View full text Add to dashboard Cite

Background: Gastric cancer (GC) is a common malignant cancer in the worldwide, especially in China. Patients with GC have poor prognosis, which is mainly due to lack of early diagnosis. Up to now, there is no good biomarker to detect GC at early stage. Apolipoprotein C1 (APOC1), a component of both triglyceriderich lipoproteins and high-density lipoproteins, is reported to be involved in numerous biological processes. Methods: Expression of APOC1 mRNA was analyzed by in silicon assay. Concentration of APOC1 in serum was measured by ELISA assay. Expression of APOC1 protein in GC tissue array was checked by immunohistochemistry. Results: It was firstly found that concentration of APOC1 in serum was significantly higher in GC than that in control. Expression of APOC1 protein was also higher in GC than that in adjacent issues of GC and normal tissues using tissues array by immunohistochemistry. In addition, the expression of APOC1 is significantly associated with clinical stage (P=0.011), tumor classification (P=0.010), as well as with the lymph node metastasis (P=0.048). Area under the curve (AUC) of receiver operating characteristic (ROC) curve of APOC1 was 0.803. Furthermore, elevated APOC1 expression in GC was found to be correlated with decreased overall survival (P=0.00214). Conclusions: All these results suggested that APOC1 might be a potential serum biomarker to diagnose GC and a potential prognostic marker for GC.

show abstract

Section: Discussionmentioning

confidence: 99%

Apolipoprotein C1 (APOC1) as a novel diagnostic and prognostic biomarker for gastric cancer

Ren

et al. 2019

Ann. Transl. Med.

View full text Add to dashboard Cite

show abstract

“…A collection of 306 specimens of OSCC was obtained from TCGA database, the level 3 RNA sequence (RNA-seq) data (.count files) was downloaded from TCGA website (https://www.cancer. gov/about-nci/organization/ccg/research/structural-genomics/tcga), and their correlated clinical information from FireBrowse database (http://firebrowse.org/) (Chabanais et al, 2018). The RNA-seq data in the TCGA database was normalized and processed using the "edgR" package (Zhang et al, 2019) prior to log 2 conversion (Yang et al, 2019).…”

Section: Data Processing For Public Databsetsmentioning

confidence: 99%

Identification of SPRR3 as a novel diagnostic/prognostic biomarker for oral squamous cell carcinoma via RNA sequencing and bioinformatic analyses

Yang

Liu

et al. 2020

PeerJ

View full text Add to dashboard Cite

Oral squamous cell carcinoma (OSCC) has always been one of the most aggressive and invasive cancers among oral and maxillofacial malignancies. As the morbidity and mortality of the disease have increased year by year, the search for a promising diagnostic and prognostic biomarker for the disease is becoming increasingly urgent. Tumorous and adjacent tissues were collected from three OSCC sufferers and we obtained 229 differentially expressed genes (DEGs) between tumor and normal tissues via high-throughput RNA sequence. Function and pathway enrichment analyses for DEGs were conducted to find a correlation between tumorigenesis status and DEGs. Protein interaction network and molecular complex detection (MCODE) were constructed to detect core modules. Two modules were enriched in MCODE. The diagnostic and prognostic values of the candidate genes were analyzed, which provided evidence for the candidate genes as new tumor markers. Small Proline Rich Protein 3 (SPRR3), a potential tumor marker that may be useful for the diagnosis of OSCC, was screened out. The survival analysis showed that SPRR3 under expression predicted the poor prognosis of OSCC patients. Further experiments have also shown that the expression of SPRR3 decreased as the malignancy of OSCC increased. Therefore, we believe that SPRR3 could be used as a novel diagnostic and prognostic tumor marker.

show abstract

“…Gene expression differences included the downregulation of protein O -fucosyltransferase 1 ( POFUT1 ), which is a key factor in the Notch1 ( NOTCH1 ) signaling pathway. This pathway is an important regulator for cell death and has been associated with poorer prognosis (Chabanais et al, 2018). Notch 1 known to be essential for maintenance of normal intestinal epithelium and is activated in primary colorectal cancer (CRC) rather than metastatic colon cancer, it may therefore may be more important for early CRC development (Suman et al, 2014).…”

Section: Resultsmentioning

confidence: 99%

Molecular pathway analysis indicates a distinct metabolic and immune phenotype in women with right-sided colon cancer

Sun

Mironova

Chen

et al. 2019

Preprint

View full text Add to dashboard Cite

34Colon cancer is the third most commonly diagnosed cancer in the United States. Recent reports 35 have shown that the location of the primary tumor is of clinical importance. Patients with right-36 sided cancers (RCCs) (tumors arising between the cecum and proximal transverse colon) have 37 poorer clinical outcomes than those with left-sided colon cancers (LCCs) (tumors arising 38 between the distal transverse colon and sigmoid colon, excluding the rectum). Interestingly, 39 women have a lower incidence of colon cancer than men do. However, women have a higher 40 propensity for RCC than men. Identification of gene expression differences between RCC and 41 LCC is considered a potential means of prognostication. Furthermore, studying colon cancer 42 sidedness could reveal important predictive markers for response to various treatments. This 43 study provides a comprehensive bioinformatic analysis of various genes and molecular 44 pathways that correlated with sex and anatomical location of colon cancer using four publicly 45 available annotated datasets housed in the National Center for Biotechnology Information's 46 Gene Expression Omnibus (GEO). We identified differentially expressed genes in tumor 47 tissues from women with RCC, which showed attenuated energy and nutrient metabolism when 48 compared to women with LCC. Specifically, we showed that the downregulation of 5' AMP-49 activated protein kinase alpha subunit (AMPKα) and downregulated anti-tumor immune 50 response in women with RCC. This difference was not seen when comparing tumor tissues 51 from men with RCC to men with LCC. Therefore, women with RCC may have a specific 52 metabolic and immune phenotype which accounts for differences in prognosis and treatment 53 response. 54 55

show abstract

POFUT1 as a Promising Novel Biomarker of Colorectal Cancer

Cited by 33 publications

References 65 publications

Apolipoprotein C1 (APOC1) as a novel diagnostic and prognostic biomarker for gastric cancer

Apolipoprotein C1 (APOC1) as a novel diagnostic and prognostic biomarker for gastric cancer

Identification of SPRR3 as a novel diagnostic/prognostic biomarker for oral squamous cell carcinoma via RNA sequencing and bioinformatic analyses

Molecular pathway analysis indicates a distinct metabolic and immune phenotype in women with right-sided colon cancer

Contact Info

Product

Resources

About